SHL Telemedicine to appoint Jason M. Bottiglieri, a highly experienced healthcare executive, as General Manager of SHL Telemedicine USA

Rhea-AI Summary

SHL Telemedicine has appointed Jason Bottiglieri as General Manager of its US subsidiary as of June 23, 2022. Bottiglieri brings over 25 years of experience in the cardiovascular device market, having held leadership roles at companies like Invatec, Spectranetics, and Infraredx. His expertise is expected to drive the growth of SHL's SmartHeart™ technology in the US market. SHL aims to leverage Bottiglieri's background to enhance the commercialization of its innovative telemedicine solutions, further strengthening its foothold in the healthcare sector.

Positive

• Appointment of Jason Bottiglieri as General Manager expected to drive growth.
• Bottiglieri brings over 25 years of executive experience in the cardiovascular device field.
• Strategic focus on enhancing SmartHeart™ technology in the US market.

Negative

• None.

Jason Bottiglieri held senior leadership roles within the cardiovascular device market including Invatec (acquired by Medtronic), Spectranetics (acquired by Philips) and Cordis, a Johnson & Johnson company.  He also served as President and CEO of Infraredx (acquired by Nipro Corporation) and InnovHeart Srl

TEL AVIV, Israel and ZURICH, June 23, 2022 /PRNewswire/ -- SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, announced that Mr. Jason Bottiglieri was nominated as General Manager of SHL Telemedicine USA, Inc., its wholly owned US subsidiary.

Jason Bottiglieri has over 25 years of commercial and executive-level management experience within the cardiovascular device field. He has extensive experience establishing and leading sales, marketing and operations teams, successfully commercializing innovative technologies in the global market.  In his most recent position, Mr. Bottiglieri held the role of Chief Commercial Officer at Elucid Bioimaging, a developer of a non-invasive artificial intelligence medical software used for cardiovascular disease diagnosis. Prior to that he served as President and CEO of InnovHeart S.r.L., a developer of transcatheter mitral valve replacement systems, and as President and CEO of Infraredx, a developer of intravascular imaging systems, acquired in 2015 by Nipro Corporation of Japan.

Jason Bottiglieri commented, "I am honored to join SHL Telemedicine to lead the SHL US business unit during this exciting period of growth. The achievements and strategic collaborations that SHL has established in a very short time form a strong foundation for the significant potential of the SmartHeart™ technology. Together with the dedicated and talented SHL US team, we will continue the work to realize the potential for SHL and establish SmartHeart™ as a household name."

Erez Nachtomy, CEO of SHL Telemedicine added, „We are pleased that Jason is joining the SHL leadership team. Jason brings with him impressive knowledge and experience in executive-level positions in the medical device field. SHL is accelerating its activity in the US and we are confident that under Jason's leadership we will significantly expand the use of our SmartHeart™ ECG technology in the US."

Further information

Fabienne Farner, IRF, Phone: +41 43 244 81 42 farner@irf-reputation.ch

About SHL Telemedicine 

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/shl-telemedicine-to-appoint-jason-m-bottiglieri-a-highly-experienced-healthcare-executive-as-general-manager-of-shl-telemedicine-usa-301573952.html

SOURCE SHL Telemedicine Ltd.

FAQ

Who has been appointed General Manager of SHL Telemedicine USA?

Jason Bottiglieri has been appointed General Manager of SHL Telemedicine USA.

What experience does Jason Bottiglieri have in the healthcare field?

Jason Bottiglieri has over 25 years of experience in the cardiovascular device market, holding senior leadership roles at several notable companies.

When was Jason Bottiglieri appointed as General Manager of SHL Telemedicine USA?

Jason Bottiglieri was appointed on June 23, 2022.

What is the focus of SHL Telemedicine's SmartHeart™ technology?

The SmartHeart™ technology focuses on personal telemedicine solutions for cardiovascular diseases.

What stock symbol is associated with SHL Telemedicine?

SHL Telemedicine is listed under the stock symbol SHLTN on the SIX Swiss Exchange.